People · Operator
Named in public records as an officer, director or promoter · active 2018–2023 · Biotechnology
| Company | Role | Sector | Stage | Raised · real | Value · est | Tied |
|---|---|---|---|---|---|---|
| Atreca, Inc. | — | Biotechnology | Series D+ | $222.2M | $5.2B | 2018 |
| CARGO Therapeutics, Inc. | — | Biotechnology | Series C | $68.8M | $1.0B | 2023 |
John Orwin at the center, the companies they're named on, and every other operator named alongside them — an interlock map of shared founding teams, boards and funds. Name-matched, so treat as a research lead.
People named alongside John Orwin on the same companies — an interlock signal (shared founding team, board, or fund). Name-matched, so verify before acting.
| Operator | Shared | Their companies |
|---|---|---|
| Heath Lukatch | 1 | 10 |
| Franklin Berger | 1 | 7 |
| Brian Atwood | 1 | 6 |
| William Robinson | 1 | 5 |
| Abraham Bassan | 1 | 4 |
| Lawrence Steinman | 1 | 4 |
| John Simpson | 1 | 3 |
| Cassandra Gianna Luca | 1 | 2 |
| Tito Serafini | 1 | 2 |
| Krishnan Viswanadhan | 1 | 2 |
| David Lacey | 1 | 2 |
| Jeffrey Walsh | 1 | 1 |
| Crystal Mackall | 1 | 1 |
| Anup Radhakrishnan | 1 | 1 |
| Susan Berland | 1 | 1 |
| Gina Chapman | 1 | 1 |
People are matched by normalized name across records; a common name may merge distinct individuals. Treat as a research lead, the same way modeled valuations are directional, not quoted.